May 23, 2025
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
Apr 14, 2025
U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab)
Mar 27, 2025
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
Mar 12, 2025
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
Mar 09, 2025
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Mar 03, 2025
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
Jan 30, 2025
U.S. FDA approves Celltrion's AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
Jan 14, 2025
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 17, 2024
U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
Jan 10, 2024
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference
Jul 28, 2020
Celltrion Selects Movilitas for Serialization and Traceability Implementations to Ensure Supply Chain Integrity and Compliance
Jun 11, 2020
Celltrion’s Subsidiary Acquires Primary Care Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited
Apr 10, 2020
Visiongain Report Provides Critical Market-led Data on the $6.6bn Biosimilar Monoclonal Antibodies Market
Sep 30, 2019
Celltrion to Launch TemixysTM Double Combination Once-Daily Tablet for HIV Treatment in the U.S.
Jul 18, 2019
Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China
Jun 11, 2019
Visiongain Report Claims There is Huge Potential Within the $57bn Biosimilar Drugs Market
Apr 08, 2019
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
Nov 29, 2018
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications
Nov 28, 2018
FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma
Sep 26, 2017
Celltrion taps Oracle Health Sciences Safety Solutions to Help Bring Cost-Effective Life-Saving and Biosimilar Drugs to Market